SCHEMBL8255103

SCHEMBL8255103

O=C(Cl)C(F)(F)c1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.45
TSHR P16473 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 1/20 0.43
HIF1A Q16665 1/20 0.43
POLB P06746 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
PPARG P37231 3/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.40
CYP19A1 P11511 1/20 0.39
ALOX15 P16050 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
FLT1 P17948 1/20 0.39
FLT4 P35916 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15957707 0.91 CES2 (0.42) MEN1KMT2ACES2CES1KDM4E
SCHEMBL9000679 0.84 CES2 (0.54) CES2CES1KDM4EALDH1A1CYP1A2
SCHEMBL13199309 0.84 KIF11 (0.43) CES2CES1
SCHEMBL164346 0.82 KCNN4 (0.48) MEN1KMT2AMAPK1CES2CES1
SCHEMBL4312243 0.82 MIF (0.50) MIFTSHRMEN1KMT2AMAPK1
Hydrochloric Acid SCHEMBL23457137 0.80 MIF (0.48) MIFTSHRMEN1KMT2AMAPK1
SCHEMBL23077098 0.80 MIF (0.44) MIFTSHRMEN1KMT2AMAPK1
SCHEMBL247104 0.79 CYP1A2 (0.48) TSHRMEN1KMT2AHIF1ACES2
SCHEMBL13199305 0.78 MAPT (0.36) KMT2APOLBCES2CES1KDM4E
SCHEMBL9000676 0.77 KIF11 (0.54) TSHRMEN1KMT2APTGDR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090124600-A1 N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists MERCK SHARP & DOHME CORP. 2009-05-14 US disclosed
US-20090124600-A1 N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists MERCK SHARP & DOHME CORP. 2009-05-14 US disclosed
WO-2006113471-A2 N-ALKYL-AZACYCLOALKYL NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2006-10-26 WO disclosed
US-5583147-A INHIBITORS OF ACYL-COENZYME A: CHOLESTEROL O-TRANSFERASE; ANTIHYPERCHOLESTEROLEMIC AND/OR ANTIATHEROSCLEROTIC AGENTS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1996-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124600-A1 N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists GRIN2B, GRIN2A, GRIN1 MIF 2810/4885TSHR 1825/4885MEN1 3674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.